Evidence map›Paper›PMID 35267574›Full record

ArticleCancers2022

Valli De Re, Lara Alessandrini, Giulia Brisotto, Laura Caggiari, Mariangela De Zorzi, Mariateresa Casarotto, Gianmaria Miolo, Fabio Puglisi, Silvio Ken Garattini, Sara Lonardi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The influence ofFrontiers in immunology · 2025
    Article
  5. Article
  6. Article
  7. HER2International journal of oncology · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Valli De ReImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-6100-9373
Lara AlessandriniSurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy.
Giulia BrisottoImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-5514-7032
Laura CaggiariImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0003-1651-6653
Mariangela De ZorziImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0002-3794-270X
Mariateresa CasarottoImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-5832-2895
Gianmaria MioloUnit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-5084-295X
Fabio PuglisiUnit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0003-0573-4938
Silvio Ken GarattiniDepartment of Oncology, University Hospital, 33100 Udine, Italy.ORCID 0000-0001-6420-0333
Sara LonardiOncology Unit 3, Veneto Institute of Oncology, Istituto Di Ricovero E Cura a Carattere Scientifico (IRCCS), 35128 Padova, Italy.ORCID 0000-0002-7593-8138
Renato CannizzaroOncological Gastroenterology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0002-2020-222X
Vincenzo CanzonieriPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0001-6010-0976
Matteo FassanSurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padova, 35128 Padova, Italy.ORCID 0000-0001-6515-5482
Agostino SteffanImmunopathology and Cancer Biomarkers, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.ORCID 0000-0002-6320-3054
Centro di Riferimento Oncologico · ITUniversity of Padua · ITUniversity of Udine · ITIstituto Oncologico Veneto · ITUniversity of Trieste · IT

Funding

5X1000 5X1000_2010_MdS funding
6 · The paper itself

Abstract

Trastuzumab is a human epidermal growth factor receptor 2 (HER2) inhibitor used to treat HER2+ metastatic gastric cancer (mGC). The present study aims to investigate the relationship between

Indexed as

CDH1E-cadherinEGFgastric cancerHER2metastasisRARARPL19survivalWNT/β-catenin pathway

Identifiers

PMID35267574
PMCPMC8909509
OpenAlexW4214545929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.